Akademik Veri Yönetim Sistemi
TURKIYE KLINIKLERI TIP BILIMLERI DERGISI, cilt.32, sa.5, ss.1260-1266, 2012 (SCI-Expanded)
Objective: Recently, the prevalence of infections by multi-drug resistant Gram-positive cocci has increased. This leads to therapeutic problems in conditions caused by these organisms. Quinupristin/dalfopristin, which is not in clinical use in Turkey, is the first parenteral streptogramin antibiotic. We aimed to investigate the susceptibility of quinopristin/dalfopristin to Gram-positive cocci isolated from clinical samples and compare it with susceptibility to other antibiotics that are used to treat Gram-positives cocci, aiming to determine the efficacy of this antibiotic. Materials and Methods: Between June 2008 and June 2009, 279 Gram-positive cocci isolated from clinical samples were included in the study. Bacteria were identified by conventional methods and automatized Vitek 2 (Biomerieux, France) system. Antimicrobial susceptibility was measured by Kirby-Bauer disk diffusion test. Methicillin resistance was detected by measuring sefoxitin susceptibility according to Clinical and Laboratory Standards Institute (CLSI) criteriae. The minimum inhibitory concentration (MIC) of penicillin, vancomycin, teikoplanin, linezolide and quinupristin-dalfopristin was detected by the E-test (AB Biodisk, Solna, Sweden). Results: Coagulase negative staphylococcus (CoNS) (103), Staphylococcus aureus (94), enterococci (50), Streptococcus pneumoniae (21) and other streptococcal strains (11) were included in the study. The susceptibility rates were 100% for methicillin sensitive staphylococci, 93% for methicillin resistant Staphylococcus aureus (MRSA), 98.1% for methycilline resistant coagulase negative staphylocci (MRCoNS), 17.1% for Enterococus faecalis, 80% for Enterococcus faecium, 85.7% for Streptococcus pneumoniae and 100% for other streptococci. All Gram-positive cocci were susceptible to glycopeptides except the two vancomycin resistant E. faecieum isolates. Conclusion: We investigated the susceptibility of Gram-positive cocci to quinupristin/dalfopristin and other antibiotics. High susceptibility of Gram-positive cocci to quinupristin/dalfopristin may allow the use of this drug as an alternative in infections due to multidrug resistant pathogens. However, further studies are required to evaluate the clinical use.